Cargando…

Durable remission with ruxolitinib in a chronic neutrophilic leukemia patient harboring a truncation and membrane proximal CSF3R compound mutation

Detalles Bibliográficos
Autores principales:	Hinze, Anna, Rinke, Jenny, Hochhaus, Andreas, Ernst, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7817602/ https://www.ncbi.nlm.nih.gov/pubmed/32577845 http://dx.doi.org/10.1007/s00277-020-04152-w

Ejemplares similares

Anti-inflammatory effects of ruxolitinib on chronic neutrophilic leukemia harboring CSF3R-T618I mutation with bilateral renal abscesses
por: Sahara, Naohi, et al.
Publicado: (2022)

Successful Allogeneic Stem Cell Transplantation with Ruxolitinib Maintenance Therapy for CSF3R T618I Mutant Chronic Neutrophilic Leukemia
por: Ye, Peipei, et al.
Publicado: (2023)

Prevalence and dynamics of clonal hematopoiesis caused by leukemia-associated mutations in elderly individuals without hematologic disorders
por: Midic, Danica, et al.
Publicado: (2020)

The concept of treatment-free remission in chronic myeloid leukemia
por: Saußele, S, et al.
Publicado: (2016)

Defective migration and dysmorphology of neutrophil granulocytes in atypical chronic myeloid leukemia treated with ruxolitinib
por: Bornemann, Lea, et al.
Publicado: (2020)

Holding CoVID in check through JAK? The MPN-approved compound ruxolitinib as a potential strategy to treat SARS-CoV-2 induced systemic hyperinflammation
por: Heidel, F., et al.
Publicado: (2020)

CSF3R T618I co-occurs with mutations of splicing and epigenetic genes and with a new PIM3 truncated fusion gene in chronic neutrophilic leukemia
por: Menezes, J, et al.
Publicado: (2013)

Treatment-Free Remission in Chronic Myeloid Leukemia Harboring Atypical BCR-ABL1 Transcripts
por: Dragani, Matteo, et al.
Publicado: (2020)

Case report: Durable response to ruxolitinib in a child with TREX1-related disorder
por: Bin Khathlan, Yasir, et al.
Publicado: (2023)

ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia
por: Schönfeld, Lioba, et al.
Publicado: (2022)

Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study
por: Ross, David M., et al.
Publicado: (2018)

Multiple myeloma with G‐CSF production mimicking chronic neutrophilic leukemia
por: Ureshino, Hiroshi, et al.
Publicado: (2021)

Durable Molecular Remission in a Lymphoid BP-CML Patient Harboring T315I Mutation Treated with Anti-CD19 CAR-T Therapy
por: Zhou, Lu, et al.
Publicado: (2019)

Durable remission of acute myeloid leukemia in an elderly patient following a limited course of azacitidine and venetoclax
por: Ehsan, Hamid, et al.
Publicado: (2022)

CSF3R, SETBP1 and CALR mutations in chronic neutrophilic leukemia
por: Cui, Yajuan, et al.
Publicado: (2014)

EZH2 in Myeloid Malignancies
por: Rinke, Jenny, et al.
Publicado: (2020)

Ruxolitinib Synergizes With Dexamethasone for the Treatment of T-cell Acute Lymphoblastic Leukemia
por: Verbeke, Delphine, et al.
Publicado: (2019)

A case of T‐cell‐Epstein–Barr virus‐haemophagocytic lymphohistiocytosis and sustained remission following ruxolitinib therapy
por: Ali, Syed, et al.
Publicado: (2023)

MPN patients harbor recurrent truncating mutations in transcription factor NF-E2
por: Jutzi, Jonas S., et al.
Publicado: (2013)

Hyaluronic acid production and characterization by novel Bacillus subtilis harboring truncated Hyaluronan Synthase
por: Amjad Zanjani, Fatemeh Sadat, et al.
Publicado: (2022)

Clonal expansion of CD8(+) T cells reflects graft-versus-leukemia activity and precedes durable remission following DLI
por: Schultze-Florey, Christian R., et al.
Publicado: (2021)

Durable and controlled depletion of neutrophils in mice
por: Boivin, Gael, et al.
Publicado: (2020)

Paradoxical activation of chronic lymphocytic leukemia cells by ruxolitinib in vitro and in vivo
por: Spaner, David E., et al.
Publicado: (2023)

Ruxolitinib for myelofibrosis
por: GU, LIAN, et al.
Publicado: (2013)

Long‐term molecular remission in a patient with acute myeloid leukemia harboring a new NUP98‐LEDGF rearrangement
por: Gallego Hernanz, Maria Pilar, et al.
Publicado: (2019)

CSF3R truncation mutations in a patient with B-cell acute lymphoblastic leukemia and a favorable response to chemotherapy plus dasatinib
por: Schwartz, Marc S., et al.
Publicado: (2020)

Characterization of the leukemogenic potential of distal cytoplasmic CSF3R truncation and missense mutations
por: Zhang, Haijiao, et al.
Publicado: (2017)

Truncated CSF3 receptors induce pro‐inflammatory responses in severe congenital neutropenia
por: Olofsen, Patricia A., et al.
Publicado: (2022)

Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia
por: Pollyea, Daniel A., et al.
Publicado: (2019)

Abrupt and durable remission of Henoch–Schönlein purpura nephritis with cyclosporine A
por: Georgaki-Angelaki, Eleni, et al.
Publicado: (2008)

Durable Remission with Immunotherapy in a Patient with Sarcomatoid Renal Cell Carcinoma
por: Nwabundo, Anusim, et al.
Publicado: (2021)

BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma
por: Raghunandan, Sharmila, et al.
Publicado: (2023)

Hypoplastic acute myeloid leukemia in an elderly patient. A long‐term partial remission with low‐dose prednisone and G‐CSF
por: Islam, Anwarul
Publicado: (2019)

Ruxolitinib: Thrombocytopenia following compassionate use of ruxolitinib: 2 case reports
Publicado: (2022)

Clinical significance of CSF3R, SRSF2 and SETBP1 mutations in chronic neutrophilic leukemia and chronic myelomonocytic leukemia
por: Ouyang, Yuan, et al.
Publicado: (2017)

Sequential Kinase Inhibition (Idelalisib/Ibrutinib) Induces Clinical Remission in B-Cell Prolymphocytic Leukemia Harboring a 17p Deletion
por: Coelho, H., et al.
Publicado: (2017)

The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation
por: La Rosée, F., et al.
Publicado: (2020)

CSF-1 regulates the function of monocytes in Crohn’s disease patients in remission
por: Nieto, Juan Camilo, et al.
Publicado: (2017)

A Case of Complete and Durable Molecular Remission of Chronic Lymphocytic Leukemia Following Treatment with Epigallocatechin-3-gallate, an Extract of Green Tea
por: Lemanne, Dawn, et al.
Publicado: (2015)

Durable remission in a patient of mixed phenotype acute leukemia with Philadelphia chromosome-positive treated with nilotinib and lenalidomide: A case report
por: Lai, Binbin, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_8563s8gfct4a9pt03qr2sv1ari